Mechanisms of resistance to cisplatin

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 478, Issue 1-2, 2001, Pages 23-43

  Kartalou, Maria ^a   Essigmann, John M ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Apoptosis; Cisplatin; DNA adducts; Double strand break repair; Drug resistance; Mismatch repair; Nucleotide excision repair; Ovarian cancer; Polymerase ; Recombinational repair; Replication bypass; Testicular cancer; Tolerance

Indexed keywords

CISPLATIN; DNA; GLUTATHIONE; OXALIPLATIN; REGULATOR PROTEIN; THIOL DERIVATIVE; WATER;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE; CONCENTRATION RESPONSE; DNA ADDUCT; DRUG MECHANISM; DRUG SENSITIVITY; DRUG UPTAKE; DRUG UTILIZATION; ENZYME INACTIVATION; EXCISION REPAIR; HUMAN; IN VIVO STUDY; MACROMOLECULE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TESTIS CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CISPLATIN; DNA ADDUCTS; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; HUMANS;

EID: 0035400270     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(01)00141-5     Document Type: Article

References (229)

1. Effect of cis-platinum(II)diamminodichloride on wild type and deoxyribonucleic acid repair-deficient mutants of Escherichia coli
2. Effects of anticancer platinum compounds on Escherichia coli strains with normal and defective DNA repair capacity
3. Mechanism of toxicity of platinum(II) compounds in repair-deficient strains of Escherichia coli
4. Reactions of the uvrABC excision nuclease with DNA damaged by diamminedichloroplatinum(II)
5. Studies on mutagenesis and repair induced by platinum analogs
6. Repair of plasmid DNA damaged in vitro with cis- or trans-diamminedichloroplatinum(II) in Escherichia coli
7. Increased sensitivity of UV-repair-deficient human cells to DNA-bound platinum products which unlike thymine dimers are not recognized by an endonuclease extracted from Micrococcus luteus
8. Host-cell reactivation of cis-diamminedichloroplatinum(II)-treated SV40 DNA in normal human, Fanconi anaemia and xeroderma pigmentosum fibroblasts
9. Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts
10. The number of platinum atoms binding to DNA, RNA and protein molecules of HeLa cells treated with cisplatin at its mean lethal concentration
11. Interactions between mammalian cell DNA and inorganic platinum compounds-I
12. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy
13. The measurement of cisplatin-DNA adduct levels in testicular cancer patients
14. Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies
15. Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy
16. Biological processing of DNA modified by platinum compounds
17. Characterization of the adducts produced in DNA be cis-diamminedichloroplatinum(II) and cis-dichloro(ethylenediamine)platinum(II)
18. Interstrand crosslinks and sequence specificity in the reaction of cis-dichloro(ethylenediamine)platinum(II) with DNA
19. Cis-diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: Quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II)
20. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: Formation, identification, and quantitation
21. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: Comparison with in vitro formation
22. The quantitative detection of various Pt-DNA adducts in Chinese hamster ovary cells treated with cisplatin: Application of immunochemical techniques
23. Sequence specificity of DNA-DNA interstrand crosslink formation by cisplatin and dinuclear platinum complexes
24. 2 inhibit DNA synthesis in cultured L1210 leukemia cells
25. In vivo effects of cis- and trans-diamminedichloroplatinum(II) on SV40 chromosomes: Differential repair, DNA-protein crosslinking, and inhibition of replication
26. 2]
27. DNA adducts of cis-diamminedichloroplatinum(II) and its trans isomer inhibit RNA polymerase II differentially in vivo
28. 2 phase and cell death induced by cisplatin
29. Influence of cis-diamminedichloroplatinum(II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells
30. 2 arrest and DNA double-strand breaks
31. Cellular pharmacology of cisplatin: Perspectives on mechanisms of acquired resistance
32. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation
33. Mechanisms associated with the expression of cisplatin resistance in a human ovarian tumor cell line following exposure to fractionated X-irradiation in vitro
34. Cellular accumulation of the anticancer agent cisplatin: A review
35. Resistance to cisplatin
36. Kinetics and mechanism of uptake of platinum-based pharmaceuticals by the rat small intestine
37. Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells
38. Decreased cisplatin uptake by resistant L1210 leukemia cells
39. Characterization of a cisplatin-resistant subline of murine RIF-1 cells and reversal of drug resistance by hyperthermia
40. Effect of hyperthermia on intracellular drug accumulation and chemosensitivity in drug-sensitive and drug-resistant P388 leukaemia cell lines
41. Hyperthermic potentiation of cis-diamminedichloroplatinum(II) cytotoxicity in Chinese hamster ovary cells resistant to the drug
42. Cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells
43. Reduced cellular uptake of cis-dichlorodiammine-platinum by benzaldehyde
44. Modulation of cis-dichlorodiammineplatinum(II)-induced cytotoxicity by benzaldehyde derivatives
45. Protection from cis-dichlorodiammineplatinum-induced cell inactivation by aldehydes involves cell membrane amino groups
46. Modifying effect of cinnamaldehyde and cinnamaldehyde derivatives on cell inactivation and cellular uptake of cis-diamminedichloroplatinum(II) in human NHIK 3025 cells
47. Reduction of cis-dichlorodiammineplatinum-induced cell inactivation by benzaldehyde
48. Reduced membrane protein associated with resistance of human squamous carcinoma cells to methotrexate and cis-platinum
49. Short-term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells
50. Adenosine triphosphate-dependent transport of leukotriene C4 by membrane vesicles prepared from cisplatin-resistant human epidermoid carcinoma tumor cells
51. Active efflux system for cisplatin in cisplatin-resistant human KB cells
52. Pleiotropic-resistant phenotype is a multifactorial phenomenon in human colon carcinoma cell lines
53. Cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines
54. The multidrug transporter, a double-edged sword
55. Identification of a membrane glycoprotein overexpressed in murine lymphoma sublines resistant to cis-diamminedichloroplatinum(II)
56. The ATP-dependent glutathione S-conjugate export pump
57. An active efflux system for heavy metals in cisplatin-resistant human KB carcinoma cells
58. Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance
59. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis
60. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds
61. Glutathione
62. Crosslinking of glutathione to DNA by cancer chemotherapeutic platinum coordination complexes
63. Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines
64. Sensitivity of testis tumour cells to chemotherapeutic drugs: Role of detoxifying pathways
65. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine-mediated glutathione depletion
66. Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion
67. Glutathione depletion reverses cisplatin resistance in murine L1210 leukemia cells
68. The relationships between glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines
69. Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and -resistant rat ovarian tumors and its relation to DNA interstrand crosslinks
70. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines
71. In vitro investigations on induction and reversal of cisplatin resistance in a rat ovarian tumor cell line
72. Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II)
73. Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells
74. Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro
75. Cellular and molecular determinants of cisplatin resistance
76. Properties of the reaction of cis-dichlorodiammineplatinum(II) with metallothionein
77. Metallothionein null cells have increased sensitivity to anticancer drugs
78. Overexpression of metallothionein confers resistance to anticancer drugs
79. Metallothionein content correlates with the sensitivity of human small lung cancer cell lines to cisplatin
80. Overexpressed human metallothionein IIA gene protects Chinese hamster ovary cells from killing by alkylating agents
81. Altered cisplatin and cadmium resistance and cell survival in Chinese hamster ovary cells expressing mouse metallothionein
82. Overexpression of metallothionein in CHO cells and its effect on cell killing by ionizing radiation and alkylating agents
83. Resistance against cis-dichlorodiammineplatinum(II) in cultured cells with a high content of metallothionein
84. Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells
85. Tumours from a cell strain with a high content of metallothionein show enhanced resistance against cis-dichlorodiammineplatinum
86. Metallothionein levels in ovarian tumours before and after chemotherapy
87. Cellular basis for differential sensitivity to cisplatin in human germ cell tumour and colon carcinoma cell lines
88. Role of metallothionein in cisplatin sensitivity of germ cell tumours
89. Do metallothioneins affect the response to treatment in testis cancers?
90. Metallothionein in testicular germ cell tumors and drug resistance
91. Molecular basis of cisplatin resistance in human carcinomas: Model systems and patients
92. Mechanisms for cisplatin-FUra synergism and cisplatin resistance in human ovarian carcinoma cells both in vitro and in vivo
93. Overexpression of DNA replication and repair enzymes in cisplatin-resistant human colon carcinoma HCT8 cells and circumvention by azidothymidine
94. Induction of fos RNA by DNA-damaging agents
95. Differential oncogene amplification in tumor cells from a patient treated with cisplatain and 5-fluorouracil
96. Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein
97. Reversal of cisplatin resistance in vivo by an anti-fos ribozyme
98. The utility of an anti-fos ribozyme in reversing cisplatin resistance in human carcinomas
99. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: Modulation of proto-oncogene expression
100. Influence of the proto-oncogene c-fos on cisplatin sensitivity
101. Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells
102. Modulation of excision repair cross-complementation group 1 (ERCC-1) mRNA expression by pharmacological agents in human ovarian carcinoma cells
103. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin
104. Resistance to anticancer drugs in NIH 3T3 cells transfected with c-myc and/or c-H-ras genes
105. Increased resistance to cis-diamminedichloroplatinum(II) in NIH 3T3 cells transformed by ras oncogenes
106. The clinical significance of flow cytometric c-myc oncoprotein quantitation in testicular cancer
107. Characterization of carboplatin-resistant sublines derived from human larynx carcinoma cells
108. The ras oncogene activation in human ovarian carcinoma
109. Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin
110. Modulation of cytotoxicity of chemotherapeutic drugs by activated H-ras
111. Activated ras oncogene and specifically acquired resistance to cisplatin in human mammary epithelial cells: Induction of DNA crosslinks and their repair
112. The v-src induces cisplatin resistance by increasing the repair of cisplatin-DNA interstrand crosslinks in human gallbladder adenocarcinoma cells
113. Transformation of rat ovarian epithelial and Rat-1 fibroblast cell lines by RAST24 does not influence cisplatin sensitivity
114. The ras mutation and platinum resistance in human ovarian carcinomas in vitro
115. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line
116. Determination of cell fate by c-Abl activation in the response to DNA damage
117. Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin
118. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage
119. New p73 variants with altered C-terminal structures have varied transcriptional activities
120. The p73 competes with p53 and attenuates its response in a human ovarian cancer cell line
121. Differential expression of p73 splice variants and protein in benign and malignant ovarian tumours
122. Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents
123. Diverse functions of JNK signaling and c-Jun in stress response and apoptosis
124. The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin
125. DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines
126. Cis-diamminedichloroplatinum(II) induces c-jun expression in human myeloid leukemia cells: Potential involvement of a protein kinase C-dependent signaling pathway
127. Apoptosis and c-jun induction by cisplatin in a human melanoma cell line and a drug-resistant daughter cell line
128. Modulation of excision repair cross-complementation group 1 (ERCC-1) mRNA expression by pharmacological agents in human ovarian carcinoma cells
129. Inhibition of the Jun kinase pathway blocks DNA repair, enhances p53-mediated apoptosis and promotes gene amplification
130. Lack of c-Jun activity increases survival to cisplatin
131. The p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA-damaging agents
132. The control of apoptosis and drug resistance in ovarian cancer: Influence of p53 and Bcl-2
133. Association between cisplatin resistance and mutations of p53 gene and reduced bax expression in ovarian carcinoma cell systems
134. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model
135. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene
136. In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts
137. Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation
138. Chemosensitivity and p53-dependent apoptosis in epithelial ovarian carcinoma
139. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents
140. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifyliine
141. DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status
142. Distinct p53-independent apoptotic cell death signalling pathways in testicular germ cell tumour cell lines
143. Expression of p53, Bcl-2 and Bax in cisplatin-induced apoptosis in testicular germ cell tumour cell lines
144. Lack of correlation between cisplatin-induced apoptosis, p53 status and expression of Bcl-2 family proteins in testicular germ cell tumour cell lines
145. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
146. A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation
147. p53-Dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells
148. Repair of cis-platinum-DNA adducts by ABC exinuclease in vivo and in vitro
149. Uvr excision repair protein complex of Escherichia coli binds to the convex side of a cisplatin-induced link in the DNA
150. Analysis of UvrABC endonuclease reaction intermediates on cisplatin-damaged DNA using mobility shift gel electrophoresis
151. The actual incision determines the efficiency of repair of cisplatin-damaged DNA by the Escherichia coli UvrABC endonuclease
152. Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3
153. Human nucleotide excision repair in vitro repair of pyrimidine dimers, psoralen and cisplatin adducts by HeLa cell-free extract
154. Repair synthesis by human cell extracts in DNA damaged by cis- and trans-diamminedichloroplatinum(II)
155. DNA crosslinked by cisplatin: A new probe for the DNA repair defect in xeroderma pigmentosum
156. Use of host cell reactivation of cisplatin-treated adenovirus 5 in human cell lines to detect repair of drug-treated DNA
157. Repair synthesis by human cell extracts in cisplatin-damaged DNA is preferentially determined by minor adducts
158. An intrastrand d(GpG) platinum crosslink in duplex M13 DNA is refractory to repair by human cell extracts
159. Differential human nucleotide excision repair of paired and mispaired cisplatin-DNA adducts
160. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease
161. Repair of cisplatin-DNA adducts by the mammalian excision nuclease
162. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy
163. Expression of nucleotide excision repair genes in CDDP-sensitive and -resistant human ovarian cancer cell lines
164. ERCC1 expression correlates with response of primary gastric cancer to cisplatin-based chemotherapy
165. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients
166. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours
167. Multiple pathways of recombination define cellular responses to cisplatin
168. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells
169. Loss of DNA mismatch repair in acquired resistance to cisplatin
170. Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line
171. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents
172. The role of DNA mismatch repair in platinum drug resistance
173. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: Correlation with replicative bypass of platinum-DNA adducts
174. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair
175. Mutator phenotype in Msh2-deficient murine embryonic fibroblasts
176. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin
177. Cloning, structural characterization, and chromosomal localization of the human orthologue of saccharomyces cerevisiae MSH5 gene
178. Cloning and characterization of the human and Caenorhabditis elegans homologs of the Saccharomyces cerevisiae MSH5 gene
179. Cloning and expression analysis of a meiosis-specific MutS homolog: The human MSH4 gene
180. Expression of the DNA mismatch repair proteins hMLH1 and hPMS2 in normal human tissues
181. Differential cellular expression of the human MSH2 repair enzyme in small and large intestine
182. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy
183. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum(II) in human ovarian cancer cell lines
184. Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: Evidence of a role for DNA repair and epidermal growth factor receptor
185. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines
186. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells
187. Repair of cisplatin-DNA adducts by protein extracts from human ovarian carcinoms
188. Enhanced DNA repair and resistance to cisplatin in human ovarian cancer
189. Enhanced repair of a cisplatin-damaged reporter chloramphenicol-O-acetyltransferase gene and altered activities of DNA polymerase α and β, and DNA ligase in cells of a human malignant glioma following in vivo cisplatin therapy
190. Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines
191. Role of carrier ligand in platinum resistance of human carcinoma cell lines
192. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy
193. Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines
194. Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients
195. DNA repair capacity and cisplatin sensitivity of human testis tumour cells
196. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines
197. Enhanced replicative bypass of platinum-DNA adducts in cisplatin resistant human ovarian carcinoma cell lines
198. Role of DNA replication in carrier-ligand-specific resistance to platinum compounds in L1210 cells
199. Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-diamminedichloroplatinum(II) DNA adducts
200. HMG1 protein inhibits the translesion synthesis of the major DNA cisplatin adduct by cell extracts
201. In vitro bypass replication of the cisplatin-d(GpG) lesion by calf thymus DNA polymerase β and human immunodeficiency virus type 1 reverse transcriptase is highly mutagenic
202. Fork-like DNA templates support bypass replication of lesions that block DNA synthesis on single-stranded templates
203. DNA polymerase β bypasses in vitro a single d(GpG)-cisplatin adduct placed on codon 13 of the HRAS gene
204. The efficiency and fidelity of translesion synthesis past cisplatin and oxaliplatin GpG adducts by human DNA polymerase beta
205. Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts
206. Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase beta
207. Strategic down-regulation of DNA polymerase beta by antisense RNA sensitizes mammalian cells to specific DNA-damaging agents
208. Overexpression of DNA polymerase beta in cell results in a mutator phenotype and a decreased sensitivity to anticancer drugs
209. Elevated DNA polymerase beta activity in a cis-diamminedichloroplatinum(II) resistant P388 murine leukemia cell line
210. Enhanced expression of DNA polymerases α and β in acquired cisplatin-resistant human colon carcinoma cells
211. Nucleotide excision repair DNA synthesis by excess DNA polymerase beta: A potential source of genetic instability in cancer cells
212. Mutagenesis in monkey cells of a vector containing a single d(GpG) cis-diamminedichloroplatinum(II) adduct placed on codon 13 of the human H-ras proto-oncogene
213. Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line
214. Cisplatin-resistance involves the defective processing of MEKK1 in human ovarian adenocarcinoma 2008/C13 cells
215. Apoptosis and c-jun induction by cisplatin in a human melanoma cell line and a drug-resistant daughter cell line
216. Overexpression of bax sensitizes breast cancer MCF-7 cells to cisplatin and etoposide
217. Apoptosis-promoting gene (bax) transfer potentiates sensitivity of squamous cell carcinoma to cisplatin in vitro and in vivo
218. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma
219. Overexpression of the Bcl-2 protein increases the half-life of p21Bax
220. Apoptosis in cancer therapy: Crossing the threshold
221. G(1) phase-dependent expression of Bcl-2 mRNA and protein correlates with chemoresistance of human cancer cells
222. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer
223. Synergistic enhancement of resistance to cisplatin in human bladder cancer cells by overexpression of mutant-type p53 and Bcl-2
224. Inhibition of Bcl-xL expression sensitizes normal human keratinocytes and epithelial cells to apoptotic stimuli
225. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio
226. Isolation of a gene associated with resistance to cisplatin
227. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo
228. Acquired multicellular-mediated resistance to alkylating agents in cancer
229. Malignant behavior and resistance to cisplatin of human ovarian carcinoma xenografts established from the same patient at different stages of the disease